

DIAGNOSTIC REPORT

PATIENT NAME : U K MALIK

REF. DOCTOR : DR. SADAR HOSPITAL

ACCESSION NO : 0707XG000764
 PATIENT ID : UKMAM051080707
 CLIENT PATIENT ID:
 ABHA NO :

AGE/SEX : 43 Years Male
 DRAWN : 13/07/2024 09:12:37
 RECEIVED : 13/07/2024 09:14:58
 REPORTED : 13/07/2024 17:48:08

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY - CBC

CBC WITH ESR (CBC+PS+ESR) EDTA WHOLE BLOOD/SMEAR

BLOOD COUNTS, EDTA WHOLE BLOOD

HEMOGLOBIN (HB)	8.2 Low	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT	2.59 Low	4.5 - 5.5	mil/ μ L
WHITE BLOOD CELL (WBC) COUNT	4.60	4.0 - 10.0	thou/ μ L
PLATELET COUNT	107 Low	150 - 410	thou/ μ L

RBC AND PLATELET INDICES

HEMATOCRIT (PCV)	24.0 Low	40 - 50	%
MEAN CORPUSCULAR VOLUME (MCV)	93.0	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	31.8	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	34.4	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	16.5 High	11.6 - 14.0	%
MENTZER INDEX	35.9		
MEAN PLATELET VOLUME (MPV)	9.2	6.8 - 10.9	fL

WBC DIFFERENTIAL COUNT

NEUTROPHILS	54	40 - 80	%
LYMPHOCYTES	39	20 - 40	%
MONOCYTES	04	2 - 10	%
EOSINOPHILS	03	1 - 6	%
BASOPHILS	0	< 1 - 2	%
ABSOLUTE NEUTROPHIL COUNT	2.48	2.0 - 7.0	thou/ μ L
ABSOLUTE LYMPHOCYTE COUNT	1.79	1.0 - 3.0	thou/ μ L
ABSOLUTE MONOCYTE COUNT	0.18 Low	0.2 - 1.0	thou/ μ L
ABSOLUTE EOSINOPHIL COUNT	0.14	0.02 - 0.50	thou/ μ L
ABSOLUTE BASOPHIL COUNT	0	0.0 - 0.1	thou/ μ L
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.4		

Sanjeew

Dr. Sanjeew Kumar
 Consultant - Pathologist &
 Laboratory Head



View Details



View Report

PERFORMED AT :

Agilus Pathlabs Reach Limited
 Sadar Hospital, Sector-1, Bokoro Steel City,
 Bokoro, 827001
 Jharkhand, India
 Tel : 7260813496
 Email : customercare.bokoro@agilus.in



ULR No. 775000009381884-0707



PATIENT NAME : U K MALIK

REF. DOCTOR : DR. SADAR HOSPITAL

ACCESSION NO : 0707XG000764
 PATIENT ID : UKMAM051080707
 CLIENT PATIENT ID:
 ABHA NO :

AGE/SEX : 43 Years Male
 DRAWN : 13/07/2024 09:12:37
 RECEIVED : 13/07/2024 09:14:58
 REPORTED : 13/07/2024 17:48:08

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BIOCHEMISTRY

LIVER FUNCTION PROFILE, SERUM

TOTAL PROTEIN	7.8	6.0 - 8.3	g/dL
ALBUMIN	5.0	3.2 - 5.0	g/dL
GLOBULIN	2.8	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO	1.8	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	8	0 - 45	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)	9	0 - 45	U/L
ALKALINE PHOSPHATASE	114	41 - 137	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT)	30	0 - 50	U/L
LACTATE DEHYDROGENASE	386	200 - 450	U/L

KIDNEY FUNCTION TEST

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN	56 High	6 - 22	mg/dL
---------------------	---------	--------	-------



Dr. Sanjeev Kumar
 Consultant - Pathologist &
 Laboratory Head

Page 4 Of 10



View Details



View Report

PERFORMED AT :

Agilus Pathlabs Reach Limited
 Sadar Hospital, Sector-1, Bokoro Steel City,
 Bokoro, 827001
 Jharkhand, India
 Tel : 7260813496
 Email : customercare.bokoro@agilus.in



ULR No. 775000008381884-0707

DIAGNOSTIC REPORT

PATIENT NAME : U K MALIK

REF. DOCTOR : DR. SADAR HOSPITAL

ACCESSION NO : 0707XG000764

AGE/SEX : 43 Years Male

PATIENT ID : UKMAM051080707

DRAWN : 13/07/2024 09:12:37

CLIENT PATIENT ID:

RECEIVED : 13/07/2024 09:14:58


ABHA NO :

REPORTED : 13/07/2024 17:48:08

Test Report Status **Final**

Results

Biological Reference Interval Units



CREATININE, SERUM
CREATININE

8.60 High

0.6 - 1.4

mg/dL

Dr. Sanjeev Kumar
Consultant - Pathologist &
Laboratory Head



View Details



View Report

PERFORMED AT :
Agilus Pathlabs Reach Limited
Sadar Hospital, Sector-1, Bokoro Steel City,
Bokoro, 827001
Jharkhand, India
Tel : 7260813496
Email : customercare.bokoro@agilus.in

ULR No.775000008381884-0707

DIAGNOSTIC REPORT


PATIENT NAME : U K MALIK

REF. DOCTOR : DR. SADAR HOSPITAL

ACCESSION NO : 0707XG000764
 PATIENT ID : UKMAM051080707
 CLIENT PATIENT ID :
 ABHA NO :

AGE/SEX : 43 Years Male
 DRAWN : 13/07/2024 09:12:37
 RECEIVED : 13/07/2024 09:14:58
 REPORTED : 13/07/2024 17:48:08

Test Report Status **Final** Results Biological Reference Interval Units



BUN/CREAT RATIO			
BUN/CREAT RATIO	6.51	5.0 - 15.0	
URIC ACID, SERUM			
URIC ACID	3.9	3.6 - 7.2	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.8	6.0 - 8.3	g/dL
ALBUMIN, SERUM			
ALBUMIN	5.0	3.2 - 5.0	g/dL
GLOBULIN			
GLOBULIN	2.8	2.0 - 4.1	g/dL

Sanjeev

Dr. Sanjeev Kumar
 Consultant - Pathologist &
 Laboratory Head

Page 6 Of 10



View Details



View Report

PERFORMED AT :
 Agilus Pathlabs Reach Limited
 Sadar Hospital, Sector-1, Bokoro Steel City,
 Bokoro, 827001
 Jharkhand, India
 Tel : 7260813496
 Email : customercare.bokoro@agilus.in



ULR No. 775000008381884-0707

DIAGNOSTIC REPORT

PATIENT NAME : U K MALIK

REF. DOCTOR : DR. SADAR HOSPITAL

ACCESSION NO : 0707XG000764
 PATIENT ID : UKMAM051080707
 CLIENT PATIENT ID :
 ABHA NO :

AGE/SEX : 43 Years Male
 DRAWN : 13/07/2024 09:12:37
 RECEIVED : 13/07/2024 09:14:58
 REPORTED : 13/07/2024 17:48:08

Test Report Status **Final** Results Biological Reference Interval Units

CALCIUM, SERUM

CALCIUM 9.7 8.4 - 10.4 mg/dL

ELECTROLYTES (NA/K/CL), SERUM

SODIUM, SERUM 139.6 137 - 145 mmol/L
 POTASSIUM, SERUM 4.02 3.6 - 5.0 mmol/L
 CHLORIDE, SERUM 105.1 98 - 107 mmol/L

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in: CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenal insufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessive sweating, severe vomiting or diarrhea), diabetes mellitus, diabetes insipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium-sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, high-dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO ₃ -), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemia, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s)

LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg,

Sanjeev

Dr. Sanjeev Kumar
 Consultant - Pathologist &
 Laboratory Head




View Details

View Report

PERFORMED AT :

Agilus Pathlabs Reach Limited
 Sadar Hospital, Sector-1, Bokoro Steel City,
 Bokoro, 827001
 Jharkhand, India
 Tel : 7260813496
 Email : customercare.bokoro@agilus.in



ULR No.775000008381884-0707



PATIENT NAME : U K MALIK

REF. DOCTOR : DR. SADAR HOSPITAL

ACCESSION NO : 0707XG000764
 PATIENT ID : UKMAM051080707
 CLIENT PATIENT ID:
 ABHA NO :

AGE/SEX : 43 Years Male
 DRAWN : 13/07/2024 09:12:37
 RECEIVED : 13/07/2024 09:14:58
 REPORTED : 13/07/2024 17:48:08

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

EIA - INFECTIOUS SECTION

HEPATITIS B SURFACE ANTIGEN, SERUM

HEPATITIS B SURFACE ANTIGEN NON REACTIVE NON REACTIVE

HEPATITIS C ANTIBODIES, SERUM

HEPATITIS C ANTIBODIES NON REACTIVE NON REACTIVE

Interpretation(s)

HEPATITIS B SURFACE ANTIGEN, SERUM-Hepatitis B is caused by infection with HBV, a enveloped DNA agent that is classified as hepadnavirus. This test detects the presence of viral surface antigen i.e HBsAg also known as "Australia antigen" in serum sample and is indicative of HBV infection, either acute or chronic.
Test Utility: HBsAg is the first serologic marker appearing in the serum 6-16 weeks following hepatitis B viral infection. In typical HBV infection, HBsAg will be detected 2-4 weeks before the liver enzyme levels (ALT) become abnormal and 3-5 weeks before patient develops jaundice. In acute cases HBsAg usually disappears 1-2 months after the onset of symptoms. Persistence of HBsAg for more than 6 months indicates development of either a chronic carrier state or chronic liver disease. The presence of HBsAg is frequently associated with infectivity. HBsAg when accompanied by Hepatitis Be antigen and/or hepatitis B viral DNA almost always indicates infectivity.
Limitations: For diagnostic purposes, results should be used in conjunction with patient history and other hepatitis markers for diagnosis of acute or chronic infection. If the antibody results are inconsistent with clinical evidence, additional testing is suggested to confirm the result. HBsAg detection will only indicate the presence of surface antigens in the serum and should not be used as the sole criteria for diagnosis, staging or monitoring of HBV infection. This test may be negative during "window period" i.e. after disappearance of anti-HBsAg antibody. The current assay being a highly sensitive test may yield a small percentage of false positive reports. Hence all HBsAg positive specimens should be confirmed with an assay based upon Neutralisation of Human anti Hepatitis B Surface antibody.
HEPATITIS C ANTIBODIES, SERUM-Hepatitis C Virus (HCV) is a blood borne flavivirus. It is one of the most important causes of post-blood transfusion as well as community acquired non-A non-B hepatitis and chronic liver failure. Although the majority of infected individuals may be asymptomatic, HCV infection may develop into chronic hepatitis, cirrhosis and/or increased risk of hepatocellular carcinoma.
Notes & Limitations: HCV antibody is typically not detected until approximately 14 weeks after infection (or 5 weeks after appearance of the first biochemical marker of illness) and is almost always detectable by the late convalescent stage of infection. A negative result may also be observed due to loss of HCV antigen, years following resolution of infection. Infants born to hepatitis C infected mothers may have delayed seroconversion to anti-HCV. Hence a negative result should be evaluated cautiously with respect to clinical findings. It is to be noted that absence of HCV antibodies after 14 weeks of exposure is strong evidence against HCV infection. Presence of HCV antibodies does not imply an active Hepatitis C infection but is indicative of both past and/or recent infection. It has been reported that as many as 90% of individuals receiving intravenous commercial immunoglobulin test falsely positive for HCV antibody. Also, patients with autoimmune liver disease may show a false positive HCV antibody result. Hence it is advisable to confirm a positive antibody result with a supplemental test. A positive result when followed by a positive supplemental test (i.e. HCV-RNA-PCR) suggests active hepatitis C infection.

****End Of Report****

Please visit www.agilusdiagnostics.com for related Test Information for this accession

Dr. Sanjeev Kumar
 Consultant - Pathologist &
 Laboratory Head



View Details



View Report

PERFORMED AT :
 Agilus Pathlabs Reach Limited
 Sadar Hospital, Sector-1, Bokoro Steel City,
 Bokoro, 827001
 Jharkhand, India
 Tel : 7260813496
 Email : customercare.bokoro@agilus.in



SADAR HOSPITAL BOKARO
CAMP 2 BOKARO



Registration No : 20240003084

Dr. Madan Prakash

Visit No : 3/ Last Visit Date : 04/04/2024 12.00 AM / Token No : 25

Medicine OPD

Room No : Main Building A, OPD Block, Ground, G. Medicine OPD 9

Name : Mr. Utpal Kumar Mallik

Registration Amount : Rs. 5

Sex/Age : 43Y 6M / M

Mobile No : 6207191417

Department : Medicine

Address : SATANPUR (JHARKHAND)

Date of Registration : 16/07/2024 09.38 AM

MLC Patient : NO

Patient Type : General

Guardian Name : AWANIKANT

MALLIK (Father)

Last Complete Collection Date/Amount : 16/01/2024 09.33 AM / Rs. 5

CBS-92
12.7.24

Report for Blood Exam ->

HIV - Non-Reactive

Preeti 03
12/7/24

Prepared By: Mrs.
Preeti Kumari

Date Time: 16/07/2024 09.38 AM



PATIENT NAME : U K MALIK		REF. DOCTOR : SELF	
CODE/NAME & ADDRESS : CR00000044	ACCESSION NO : 0031XG011166	AGE/SEX : 43 Years Male	
SRL REACH LTD OPD PATIENTS	PATIENT ID : UKMAM14078131	DRAWN : 13/07/2024 09:07:00	
SADAR HOSPITAL, BOKORO, SECTOR - 1, BOKORO	CLIENT PATIENT ID:	RECEIVED : 14/07/2024 12:25:32	
STEEL CITY,	ABHA NO	REPORTED : 14/07/2024 15:04:04	
BOKARO 827001			
7260813496			

CLINICAL INFORMATION :

0707XG000764

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BIOCHEMISTRY

IRON, SERUM

IRON	58 Low	65 - 175	µg/dL
-------------	---------------	-----------------	--------------

METHOD : FERENE

Interpretation(s)

IRON, SERUM-Serum iron test is useful for etio- morphological diagnosis of anemias, in hemochromatosis, in hemosiderosis and in acute iron toxicity. Serum iron is recommended to be correlated with Total Iron Binding Capacity (TIBC) for evaluation of iron deficiency.

****End Of Report****

Please visit www.agilusdiagnostics.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form
5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
8. Test results cannot be used for Medico legal purposes.
9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd
Fortis Hospital, Sector 62, Phase VIII,
Mohali 160062

Dr. Anvesha Chatterjee

Dr. Anvesha Chatterjee, MD, DipRCPPath (Histopathology) Pathologist

Dr. Chaitali Ray

Dr. Chaitali Ray, PHD Chief Biochemist cum MRQA



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd
P S Srijan Tech Park Building, Dn-52, Unit No. 2, Ground Floor, Sector V, Salt Lake,
Kolkata, 700091
West Bengal, India
Tel : 9111591115, Fax : 30203412





(13)
45.1 kg

Dr. Mukteshwar Rajak

M.B.B.S., M.D (MEDICINE)
D.M. (NEPHROLOGY)
EX. H.O.D (NEPHROLOGY)
JOINT DIRECTOR (BGH)
Life Member API, Life Member ISN
Sr. CONSULTANT NEPHROLOGIST
TRANSPLANT PHYSICIAN

BP 110/70 mm/Hg

Pulse 80/min

SPO₂ 96%

Date: 17/7/24

Patient Name: Utpal K. Mallik Age: 43y Sex: M

- Hb% 8.2 g/dl
- Sr. creatinine 8.4 mg/dl
- H₂O₂
- H₂O₂
- H₂O₂

Δ • HTN
• CKD 2nd Pr MHO
• 2nd Broni s.

- ① SOBASTIS 1/2 — (60)
 - ② Tab. RANIT — (30)
 - ③ TB/CP - Shelcal CP (60) 1-1
 - ④ Tab. CVOTA — (60)
 - ⑤ Tab. Folic acid — (30) 1-1
 - ⑥ B. complex — (30)
 - ⑦ H.O. (Mucopolysaccharide)
- 1
17/7/24

Fees Valid Up to 15 days

दवा मिलने का स्थान :
Shubh Vinayak Medicine

Plot No.-180, Co-operative Colony

R.N.B HOSPITAL Help line No.

06542255060 9153899691

